{"id":"NCT03191786","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy","officialTitle":"A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab Compared With Chemotherapy in Patients With Treatment Naïve Advanced or Recurrent (Stage IIIb Not Amenable for Multimodality Treatment) or Metastatic (Stage IV) Non-Small Cell Lung Cancer Who Are Deemed Unsuitable for Platinum-Containing Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-09-11","primaryCompletion":"2022-04-30","completion":"2023-10-25","firstPosted":"2017-06-19","resultsPosted":"2023-05-17","lastUpdate":"2024-10-23"},"enrollment":453,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-Small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody","otherNames":["MPDL3280A"]},{"type":"DRUG","name":"Vinorelbine","otherNames":["Navelbine®"]},{"type":"DRUG","name":"Gemcitabine","otherNames":["Gemzar®"]}],"arms":[{"label":"Atezolizumab","type":"EXPERIMENTAL"},{"label":"Single Agent Chemotherapy (Vinorelbine or Gemcitabine)","type":"ACTIVE_COMPARATOR"}],"summary":"This Phase III, global, multicenter, open-label, randomized, controlled study will evaluate the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 \\[anti-PD-L1\\] antibody) compared with a single agent chemotherapy regimen by investigator choice (vinorelbine or gemcitabine) in treatment-naïve participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are deemed unsuitable for any platinum-doublet chemotherapy due to poor performance status (Eastern Cooperative Oncology Group \\[ECOG\\] performance status of 2-3).","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"From randomization up to death from any cause (up to approximately 55 months)","effectByArm":[{"arm":"Atezolizumab","deltaMin":10.3,"sd":null},{"arm":"Single Agent Chemotherapy (Vinorelbine or Gemcitabine)","deltaMin":9.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.025"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":null},"locations":{"siteCount":91,"countries":["Argentina","Belgium","Brazil","Bulgaria","Canada","China","Colombia","Czechia","Denmark","Germany","India","Ireland","Italy","Kazakhstan","Luxembourg","Mexico","Poland","Portugal","Romania","Slovakia","Spain","Switzerland","United Kingdom","Vietnam"]},"refs":{"pmids":["39532375","37423228","37419867"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":147,"n":300},"commonTop":["Anaemia","Decreased appetite","Fatigue","Constipation","Cough"]}}